Comprehensive findings from CV, kidney and HF trials with SGLT2 inhibitors since 2015 have persuaded diabetes, CV, kidney and HF clinical guideline writing committees to revise and update their recommendations more frequently than previous iterations. Here, SLC5A2 is linked to hydrops fetalis.